Repatha and Pulmonary thrombosis - a phase IV clinical study of FDA data

Summary:

Pulmonary thrombosis is reported as a side effect among people who take Repatha (evolocumab), especially for people who are female, 60+ old, also take Eliquis, and have Hyperlipidaemia.

The phase IV clinical study analyzes which people have Pulmonary thrombosis when taking Repatha. It is created by eHealthMe based on reports of 155,838 people who have side effects when taking Repatha from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,258 Repatha users. Check the latest studies of Repatha.

What is Pulmonary thrombosis?

Pulmonary thrombosis (scarring in the lungs) is found to be associated with 713 drugs and 715 conditions by eHealthMe. Check the latest studies of Pulmonary thrombosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

155,838 people reported to have side effects when taking Repatha.
Among them, 20 people (0.01%) have Pulmonary thrombosis.

Could Repatha cause Pulmonary thrombosis?

Among these 20 people:

What is the gender of people who have Pulmonary thrombosis when taking Repatha? *

female: 55 %
male: 45 %

What is the age of people who have Pulmonary thrombosis when taking Repatha? *

What are other drugs people take besides Repatha? *

What are other side effects people have besides Pulmonary thrombosis? *

Thrombosis (formation of a blood clot inside a blood vessel): 3 people, 15.00%
Weakness: 3 people, 15.00%
Weight Decreased: 2 people, 10.00%
Drug Ineffective: 2 people, 10.00%
Gallstones (stone formation by bile component): 2 people, 10.00%
High Blood Pressure: 2 people, 10.00%
Loss Of Consciousness: 2 people, 10.00%
Neoplasm Progression (growth of tumour): 2 people, 10.00%
Pain: 2 people, 10.00%
Pain In Extremity: 2 people, 10.00%

What are the existing conditions these people have? *

Hyperlipidaemia (presence of excess lipids in the blood): 5 people, 25.00%
Renal Cancer Metastatic (cancer of kidney spreads to other part): 2 people, 10.00%
Neuralgia (pain in one or more nerves): 2 people, 10.00%
Nausea (feeling of having an urge to vomit): 2 people, 10.00%
High Blood Pressure: 2 people, 10.00%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 10.00%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 2 people, 10.00%
Renal Cell Carcinoma (a kidney cancer): 1 person, 5.00%
Multiple Myeloma (cancer of the plasma cells): 1 person, 5.00%
Low Density Lipoprotein Increased (cholesterol increased in blood): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and have Pulmonary thrombosis?

- Check whether Pulmonary thrombosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Repatha:

Repatha (156,258 reports)

Browse all side effects of Repatha:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary thrombosis:

Pulmonary thrombosis (713 drugs)

Browse all the conditions that are associated with Pulmonary thrombosis:

Pulmonary thrombosis (715 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on evolocumab (the active ingredients of Repatha) and Repatha (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.